KLRK1 and neoplasm: Specific delivery of IL-2 with the NKG2D-Fc system led to the expansion of tumour antigen-specific CD8+ T cells at the tumour loci and an improved therapeutic anti-tumour effect generated by the therapeutic DNA HPV vaccine [111].